Mizuho analyst Dan Dolev reiterated Neutral on Global Payments Inc (NYSE:GPN) with a $132 price target reflecting weak and unreliable results. The 3Q 2022…
Tumor tissues were analyzed to determine potential predictors of treatment response to MN-166 (ibudilast) and temozolomide (TMZ) combination treatment.
Pre-treatment tumor tissues were obtained from the resected